Lazard U.S. Equity Concentrated Portfolio Q1 2025 Commentary
Source: SeekingAlpha
2025-05-22 18:30:00 ET
Summary
- In the first quarter, the Lazard US Equity Concentrated Portfolio underperformed its benchmark, the S&P 500 Index.
- The US equity market receded in the first quarter, as US tariff plans impacted outlooks for corporate spending and economic growth.
- Decisions made under pressure are often not the best decisions, and while we don’t shy away from them when the need arises, we try to avoid them.
Market Overview
The US equity market receded in the first quarter, as US tariff plans impacted outlooks for corporate spending and economic growth....
Read the full article on Seeking Alpha
For further details see:
Lazard U.S. Equity Concentrated Portfolio Q1 2025 Commentary
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
1.88% G/L:
$59.48 Last:
305,219 Volume:
$58.47 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
